Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
AbbVie (NYSE: ABBV) has entered into an exclusive licensing agreement with IGI Therapeutics SA for ISB 2001, a first-in-class CD38×BCMA×CD3 trispecific antibody currently in Phase 1 clinical trials for relapsed/refractory multiple myeloma.
Under the agreement, AbbVie gains exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China. IGI will receive an upfront payment of $700 million and is eligible for up to $1.225 billion in milestone payments, plus tiered, double-digit royalties on net sales.
ISB 2001 was developed using IGI's proprietary BEAT® protein platform and represents a new frontier in immuno-oncology by engaging multiple targets simultaneously.
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Capstan Therapeutics in a deal valued at up to $2.1 billion in cash. The acquisition centers on Capstan's lead asset CPTX2309, a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy currently in Phase 1 clinical trials for B cell-mediated autoimmune diseases.
CPTX2309 delivers mRNA encoding an anti-CD19 chimeric antigen receptor to CD8-expressing cytotoxic T cells in vivo, offering a novel approach to treating autoimmune conditions. The therapy aims to deplete autoreactive antibody-producing pathogenic memory B cells and achieve immune system reset without requiring lymphodepletion preconditioning or complex ex vivo manufacturing.
The acquisition also includes Capstan's proprietary tLNP platform technology designed for RNA payload delivery. The transaction is subject to customary closing conditions, including Hart-Scott-Rodino Antitrust Improvements Act requirements.
[ "Acquisition of potential first-in-class therapy CPTX2309 currently in Phase 1 trials", "Technology eliminates need for complex ex vivo manufacturing and lymphodepletion preconditioning", "Platform has potential to treat wide range of autoimmune diseases", "Acquisition includes valuable proprietary tLNP platform technology" ]AbbVie (NYSE:ABBV) announced that the FDA has accepted for review the supplemental premarket approval (sPMA) application for SKINVIVE by JUVÉDERM® to reduce neck lines and improve neck appearance. The product is currently approved in the U.S. for improving cheek skin smoothness in adults over 21.
The application is supported by a successful clinical study where 80% of patients achieved at least a 1-grade improvement in horizontal neck lines at month 1, and nearly 90% reported improvement in neck appearance. Treatment-emergent adverse events were mild and consistent with the known safety profile.
If approved, SKINVIVE by JUVÉDERM® would become the first hyaluronic acid injectable treatment specifically targeting neck lines, addressing a significant market need as neck appearance is a top concern among aesthetic treatment seekers.
AbbVie (NYSE: ABBV) has scheduled its second-quarter 2025 financial results announcement for Thursday, July 31, 2025, before market opening. The company will host a live earnings conference call at 8 a.m. Central time. Investors can access the webcast through AbbVie's Investor Relations website at investors.abbvie.com, with an archived version available later that day.